Project Grant R01AG094740
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $680K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institute on Aging awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $463,000 under the Aging Research program (CFDA 93.866) on May 1, 2026, to support research investigating chromatin mechanisms of cytoplasmic chromatin fragments during senescence and aging. The research examines how chromatin fragments transit from the nucleus to the cytoplasm in senescent and aged cells, activating the cGAS-STING immune pathway and driving chronic...
- The National Institute on Aging awarded The General Hospital Corporation (Massachusetts General Hospital) $269,452 under the Aging Research program (CFDA 93.866) on February 18, 2026, to conduct research on proteomic aging and frailty prediction. The project integrates large-scale genetic, multi-omic, and clinical data from the UK Biobank, Multi-Ethnic Study of Atherosclerosis (MESA), FinnGen, and All of Us (combined N=70,225) to investigate the biological underpinnings of proteomic aging and...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded $533,500 to the Buck Institute for Research on Aging on July 15, 2026, under the Aging Research program (CFDA 93.866). The award funds examination of the role of autonomic innervation in muscle stem cell aging. The research investigates the functional link between autonomic nervous system neurons and muscle stem cells using Drosophila melanogaster as a model organism. The project will refine...
- The National Institute on Aging awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $453,750 in Project Grant funding on February 15, 2026, under the Aging Research program (CFDA 93.866). The award funds a study establishing a cohort of 100 older Chinese immigrants aged 65 and above to examine cognitive outcomes, sleep quality, and circadian function in the "zeroth generation" immigrant population—aging parents of first-generation immigrant...
- The National Institute on Aging awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $3,558,232 under the Aging Research program (CFDA 93.866) on August 5, 2026, to conduct the WHIMSY-AD Study examining menopause and related midlife risk factors and their impact on later-life Alzheimer's disease pathology and cognition. The study recontacts 700 participants from the Women's Health Initiative Memory Study of Younger Women (WHIMSY), now aged 75–84 years,...
- The National Institute on Aging awarded $660,000 to The General Hospital Corporation (doing business as Massachusetts General Hospital) on August 15, 2026, under the Aging Research program (CFDA 93.866) to develop machine learning models for single-cell aging clocks that track aging trajectories across multiple organs and species. The recipient will integrate large-scale, publicly available single-cell transcriptomics datasets from mouse, rat, human, and invertebrate aging models totaling...
- The National Institute on Aging awarded $237,270 to The General Hospital Corporation, doing business as Massachusetts General Hospital, on August 20, 2026, under the Aging Research program (CFDA 93.866) to investigate a novel mechanism of autophagic degradation in cellular senescence. The research will examine how autophagy—a cellular self-digestion process—functions in senescent cells and how covalent conjugation of ATG8 family proteins to autophagy substrates facilitates protein degradation...
- The National Institute on Aging awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $1.655 million on June 1, 2026, under the Aging Research program (CFDA 93.866) to develop and validate the TARGET protocol, a personalized thromboprophylaxis approach for elderly patients undergoing endovascular revascularization for peripheral artery disease. The funded research addresses post-surgical thrombosis following endovascular intervention, which occurs in...
- The National Institute on Aging awarded Harvard Pilgrim Health Care, Inc. $706,310 on May 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a longitudinal study examining the interplay among reproductive, molecular, and chronological age in relation to aging-related conditions in women. The study leverages existing high-quality data and biosamples from a well-phenotyped population of over 850 women followed from recruitment in early pregnancy in 1999–2002 for over two decades....
- The National Institute on Aging, part of the Department of Health and Human Services, awarded The Trustees of Columbia University in the City of New York $149,190 on August 6, 2026, under the Aging Research program (CFDA 93.866) to investigate the molecular mechanisms by which NBR2, a long non-coding RNA, contributes to ovarian aging. The research addresses female-specific health conditions through genome-wide association studies and functional genomic studies in human ovarian cell models. The...